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Abstract
Drug-induced ECG changes may affect all components of the ECG curve. The attention of
regulatory agencies, researchers and clinicians has been directed towards drug-induced QT-inter-
val prolongation and its well-documented proarrhythmia. This presentation focuses on drug-
induced changes, i.e., morphology, amplitude and QRS complex duration (QRSd). A great
variety of pharmacological agents (e.g., class IA and IC antiarrhythmics, antihistamines,
antidepressants, antipsychotics) exert an influence on the QRSd. The QRSd is assessed by
a variety of ECG methodologies. Standardization of measurements of QRSd ensures the
comparability of results by different ECG modalities, and of serial QRSd assessments. Some
analgesics and hypoglycemic agents influence the amplitude of QRS complexes by way of their
propensity to cause peripheral oedema (extracardiac mechanism). Perhaps a new culture could
evolve in which the entire ECG curve, from the onset of the P-wave to the offset of the U-wave,
will be used in the evaluation and monitoring of drug safety, with emphasis primarily on the
standard ECG. (Cardiol J 2008; 15: 505–509)
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Introduction
In this presentation, remarks will be limited to
drug-induced changes in QRS duration (QRSd),
morphology and amplitude. Prolongation of the QT-
-interval (QT) has been primarily emphasized by
regulatory agencies, pharmaceutical industry, rese-
archers and clinicians, due to its documented asso-
ciation with proarrhythmia [1]. The role of changes
in the QRSd, morphology and amplitude in the eva-
luation and monitoring of drugs is discussed, and
some comments about measuring the QRSd are
presented.
Prolongation of QRS duration
The QRSd reflects the duration of ventricular
depolarization, and its measurement differentiates
normal intraventricular conduction (< 100 ms) from
bundle branch blocks (BBB) and intraventricular
conduction delays (IVCD) [2]. Depolarization of
atrial and ventricular myocytes depends mainly on
the fast response inward Na+ current, which deter-
mines the slope of phase 0 and the amplitude of
action potentials. Blockade of the Na+ current le-
ads to attenuation of the rate and magnitude of de-
polarization, which in turn slows the transmission
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of action potentials among myocytes, with a resul-
tant decrease in the velocity of the excitation con-
duction, and prolongation of the QRSd. This slow
spreading of depolarization underlies the suppres-
sion or interruption of proarrhythmic re-entry, but
could also result in incessant ventricular arrhyth-
mias (VA). Many antiarrhythmic drugs exert an ef-
fect by blocking the Na+ current, and some prolon-
gation of QRSd is an indicator of their desired
pharmacologic effect. The question is whether pro-
longation of the QRSd is indicative of proarrhyth-
mia to the same degree as it is in the case in QT
prolongation, and thus could be employed in drug
monitoring independently of associated QT. Some
non-antiarrhythmic cardiac and noncardiac drugs
also block the Na+ current and thus prolong the
QRSd; for such agents these effects are considered
adverse responses of their pharmacodynamic pro-
file, particularly when they lead to VA. In general,
prolongation of the QRSd is less frequent than pro-
longation of the QT, although occasionally one of
these 2 ECG parameters can be prolonged at the
exclusion of the other. Usually, the standard ECG
(ECG) is less sensitive than the signal-averaged ECG
(SAECG) in documenting prolongation of the QRSd.
Class I drugs (Na+ current blockers) of the
Vaughan-Williams antiarrhythmics classification
prolong the QRSd with the agents of subclasses IC,
IA, and IB, producing this effect in a descending
order of magnitude, based on the intensity of the
Na+ channel blockade they induce. With the excep-
tion of type IB drugs (lidocaine, tocainide, mexile-
tine, phenytoin), all class I drugs result in signifi-
cant QRSd prolongation. Type IC drugs (flecainide,
propafenone, moricizine) lead to larger changes in
the SAECG QRSd prolongation than IA (quinidine,
procainamide, disopyramide) or IB, and the combi-
nation of IA and IB drugs. These changes in the
SAECG reflect prolongation of the initial portion of
the QRS complex and late potentials, i.e., they in-
duce a global slowing of ventricular activation. Pro-
cainamide, a class IA agent, prolongs the SAECG
QRSd in patients with inducible VA, with a > 15%
prolongation being the best parameter that identi-
fies effectively treated patients [3]; in other studies
of class I antiarrhythmic drugs, SAECG QRSd pro-
longation failed to predict drug efficacy, although
these drug-induced changes may be helpful in ca-
tegorizing antiarrhythmic agents [4, 5]. Changes in
the serum concentration of class I agents and
SAECG QRSd correlated well in patients receiving
chronic care, thus rendering repeat blood drug con-
centration measurements unnecessary [6]. Class IA
agents also have a K+ channel blocking effect, which
is responsible for the prolongation of the effective
refractory period (ERF) induced by these drugs.
Class IC drugs, flecainide and pilsicainide prolong
the SAECG QRSd. Class III (K+ channel blockers
responsible for phase 3 of repolarization) drugs also
prolong the QRSd, since they also possess some
Na+ blocking effect. Many class III drugs have me-
chanisms of action that are shared with drugs
found in the other classes. For example, amiodaro-
ne, a Class III antiarrhythmic, also exerts Na+ and
Ca++ channel blocking actions. Class III antiarrhy-
thmic agents (amiodarone, bretylium, sotalol, do-
fetilide, ibutilide) block the K+ channel repolarizing
currents and prolong the action potentials and the
ERP. Amiodarone prolonged the SAECG QRSd in
patients with old myocardial infarction, who under-
went programmed ventricular stimulation, and such
changes were more pronounced in patients with no
inducible VA, while the ECG was not sensitive in
detecting amiodarone induced QRSd prolongation [7].
However, dofetilide (a pure Class III antiarrhyth-
mic agent) did not change the SAECG, and no
SAECG parameter predicted the results of pro-
grammed ventricular stimulation [3]. Azimilide,
a class III antiarrhythmic agent, increased the ac-
tion potential duration, QT, and ERP, but did not
affect the QRSd [8].
Noncardiac drugs also have an effect on the
QRSd. The histamine H1 receptor antagonist aste-
mizole markedly depresses the rate of rise of the
action potential (Vmax) and prolongs the QRSd,
with terfenadine showing smaller such effects. The
effect of different histamine H1 receptor antagoni-
sts on the ERP, and thus on QT, is variable. Over-
dose with dextropropoxyphene, an opioid which is
used in combination with the analgesic acetamino-
phen, and is a cause of hospital admissions and de-
ath in Australia and the UK, leads to a dose-depen-
dent prolongation of the QRSd, but no changes in
the QT [9]. Coadministration of some of these drugs
with the antifungal itraconazole, or other cytochro-
me P450 3A4 inhibitors, intensifies their effects on
the QRSd [10]. The “prokinetic” drug cisapride did
not have an effect on the QRSd while it prolonged
the QT [11]. Amitriptyline in combination with
a benzodiazepine was the most common antidepres-
sant taken by patients, and led to a prolonged QRSd
and QT, but no arrhythmias were observed in pa-
tients with an overdose [12]. The tricyclic antide-
pressants dosulepin and amitriptyline may cause
fatal poisoning and prolong both the QRSd and
QT [13]. The antidepressant maprotiline prolongs
the QRSd without causing arrhythmias [14].  Desi-
pramine, an antidepressant, was associated with
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prolongation of the QRSd and QT, although the cor-
relation of drug levels and the ECG parameters was
poor [15]. ECG changes with tricyclic antidepres-
sant agents are attributable primarily to the Na+
channel blockade caused by these agents. The ma-
jority of patients at significant risk of developing
cardiac or neurological toxicity from these agents
will have a QRSd > 100 ms, or a rightward shift of
the terminal 40 ms of the frontal plane QRS com-
plex vector [16]. Some antimalarial drugs delay
ventricular depolarisation slightly (class IC effect),
resulting in prolongation of the QRSd, and some
have ventricular repolarisation (class III) effects.
The anthracycline daunorubicin induces a signifi-
cant and progressive prolongation of the QRSd. The
ECG appears to be of limited value in the assessment
of cardiac toxicity with Adriamycin therapy [17].
A large number of other drugs, tricyclic and tera-
cyclic antidepressants, antipsychotics, and antico-
nvulsives prolong the QRSd via a blocking effect on
cardiac Na+ currents. Thus, the above listing of
some drugs prolonging the QRSd is a small sample
of what the literature comprises on this topic.
Measurement of QRS complex duration
Many ECG modalities have been employed in
the measurement of the QRSd (the ECG, the SAECG,
the Frank vectorcardiogram (VCG), the exercise
ECG and the Holter ambulatory ECG). Measure-
ments are carried out manually or executed by au-
tomation-based algorithms [2]. Single specific
leads, groups of leads or the entire array of leads of
the ECG are employed. Often, automated algori-
thms calculate a “global” QRSd, which is based on
different leads, for each manufacturer of electrocar-
diographs. When the SAECG is employed, informa-
tion about late potentials is referred to, along with
the duration of the filtered total QRS complex.
Manual measurements are made from hard copies,
digitized ECGs or digital ECGs on the computer
screens. Magnification is employed on the hard
copies or the computer screens. Hand-held or elec-
tronic callipers are utilized. ECG recording at do-
uble or higher speed, at standard or double calibra-
tion, is occasionally used. Occasionally no mention
is made in literature reports of the methods used
to measure the QRSd. The definition of offset is less
of a problem in the measurement of the QRSd than
it is with the QT. Nevertheless, the definition of
both the onset and offset is problematic since ma-
nual methods use a subjective estimate as to whe-
re these points belong. Automated algorithms rely
either on computer algorithms using QRS derivati-
ves or spatial vector velocity parameters [2, 18, 19].
A spectral method, based on the fact that the QRS
complexes comprise significant frequencies greater
than 50 Hz, used a 50–300 Hz digital filter and an
SAECG to reduce in the noise and, to QRSd me-
asurements [18, 19]; the results by this method
had an excellent correlation with carefully made
visual determinations of QRSd carried out in ECG
recordings at high speed and gain. No work has
been done on comparing methods such as the one
described herein based on spectral content with
others using the morphology or slope of QRS com-
plexes. Since QRSd prolongation with drugs is
often frequency dependent [20], comparisons of
QRSd values, when drugs are evaluated, should
take the heart rates into account. Casual observa-
tions of data from exercise ECGs or Holter ambu-
latory ECGs suggest a dynamic character of QRSd
over time. Increasing QRSd with increasing heart
rates is not unusual even in seemingly normal sub-
jects, and thus the evaluation of changes in the
QRSd should always be considered in conjunction
with the corresponding heart rates.
Since studies evaluating drugs employ the ECG
and/or the SAECG, it is important to evaluate how
the different ECG modalities compare in reference
to measurements of QRSd. Comparison of the QRSd
measured by ECG, VCG and SAECG in patients
with prior myocardial infarction, excluding patients
with bundle branch block (BBB) [21], showed that
the QRSd was the same by SAECG and VCG, but
longer than the QRSd by ECG, in patients without
spontaneous or inducible VA; QRSd was longer by
SAECG than VCG, and the QRSd by the latter was
longer than the QRSd by the ECG in patients with
spontaneous or inducible VA; the QRSd was longer
by all 3 modalities in patients with spontaneous VA
than in patients without spontaneous or inducible
VA; a QRSd on VCG ≥ 110 ms and on ECG ≥ 100 ms
had a sensitivity of 93% and 77% and a specificity
of 83% and 85%, respectively, for predicting an
abnormal SAECG result, and thus measurements
of QRDd from any of these 3 ECG modalities could
detect the patients with myocardial infarction pro-
ne to VA. Extrapolation of the results of this study
to the setting of drug evaluation or monitoring sug-
gests that any of these 3 ECG methodologies can
be used in serial QRSd measurements, providing
that one keeps in mind that the QRSd is inherently
shorter by ECG than by SAECG or VCG. Sources
of variation in values of QRSd from serial ECG re-
cordings in the same patients are: the inherent
over-time variation of QRSd, the different leads
used for its calculation by different proprietary
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automated algorithms, and the failure to adhere to
the recommended placement of precordial electrodes
on the chest wall. Age- and gender-specific normal
values have been published [2]. Exercise often in-
creases QRSd, and some of these changes lead to
morphology changes of the QRS complexes or to
various degrees of BBB or IVCD. SAECG-based
measurements of QRSd are considered more accu-
rate and have been used extensively in research
(vide supra). In addition, ambulatory ECG-based
measurements of QRSd are occasionally used and
this provides the advantage of a dynamic asses-
sment of this parameter. These two latter techno-
logies should not replace the standard ECG-based
assessment of QRSd, which should be used routi-
nely and repeatedly by all physicians in patients
treated with drugs known to influence this measu-
rement. There is some literature on QRS disper-
sion and QRS/QT dispersion [22]; however, these
parameters have not found an application in drug
research. Due to the much clearer inscription of the
offset of QRS complexes, in contrast to QT-inter-
vals, the problems in the measurement of QRSd
are much smaller than those encountered with QT
measurements. Consensus among manufacturers of
electrocardiographs about the algorithm of the “glo-
bal” QRSd calculation will provide comparability of
values generated by different ECG machines. The
value of changes in the QRS complexes, as predic-
tors of drug-induced arrhythmogenicity, will be
enhanced by studying frequently obtained ECGs in
terms of QRSd and morphology and amplitude of the
QRS complexes in both research and practice. The
voluminous literature on drug-induced QT either
does not include information on the QRS complex,
or when it does, such information is not analyzed
in a multivariate fashion in order to evaluate the in-
dependent proarrhythmic role of QRSd. Such scru-
tiny of the ECG should be done with pari passu
observations of the corresponding QTs. Drug-indu-
ced increase in QRSd is probably less sensitive than
increase in QT, but it may have an independent
value in the evaluation of certain drugs.
A number of questions in reference to various
drugs need to be settled: 1) Does the QRSd have
any predictive value, independent of the QT?
2) Does the QRSd have an additive value when it is
used in conjunction with the QTs? 3) At what per-
centage increase of QRSd should one have concerns
about the continuation of drug(s) administered?
4) Does a change in the QRSd affect the correspon-
ding QT, and thu can the J-T interval also be asses-
sed in parallel with the QT? Indeed, it has been
shown that an increase in QT could occasionally be
accounted for primarily by the corresponding incre-
ase in the QRSd, without any change in the J-T in
patients treated with IC and IA drugs [23]. Answers
to some of these questions could probably emana-
te from the data of published studies on QTs and
drug-induced proarrhythmia. Such a correlative
approach in future studies and in practice may en-
hance our predicting power of detecting drug-indu-
ced proarrhythmia.
Changes in QRS amplitude
Intuitively, drugs blocking the Na+ peak cur-
rent and attenuating the velocity of phase 0 slope
and the amplitude of action potentials are expected
to cause a reduction of the amplitude of QRS com-
plexes; however, no literature on this is available,
particularly in reference to the ECG. There was
a decrease in the voltage of the entire filtered QRS
in SAECG with tricyclic antidepressants [24]. Ne-
vertheless, a reduction in the QRS amplitude of the
ECG has been noted with some drugs which have
in common the development of peripheral oedema
(PERED) as a side effect. It is important to note that
such a reduction is extracardiac in mechanism due
to the effect of the body volume conductor on the
cardiac potentials as they are transferred to the
body surface [25]. Rofecoxib, a nonsteroidal anti-
inflammatory drug, which is a selective COX-2 in-
hibitor, may produce reversible PERED in associa-
tion with reversible reduction of the amplitude of
QRS complexes [26]. In addition, thiazolidinediones,
the antidiabetic drugs, induce reversible PERED,
which leads to attenuation of QRS complexes [27].
One can only speculate that such ECG manifesta-
tions are common with other drugs with a propen-
sity of PERED as a side effect, and this deserves
evaluation. Another matter that needs considera-
tion is the changes in QRSd resulting from chan-
ges in the QRS amplitude. Such changes in the
amplitude lead to a shortening of QRSd [28], pro-
bably due to the failure to include in the QRSd the
measurement of a portion of the onset and offset of
the QRS complexes, which, by attenuation of the
QRS amplitude, renders them indistinguishable from
“noise”. This speculation was confirmed in a study
of artificial attenuation of the QRS amplitudes,
which resulted in a shortening of the QRSd [29].
The above apply to patients with congestive heart
failure or other oedematous states in which the
possible drug-induced changes in the QRSd should
be interpreted in the context of the associated at-
tenuation/augmentation of the magnitude of the
QRS complexes.
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Changes in QRS morphology
There is no literature about drug-induced QRS
morphology changes. However, one can speculate
that changes in the velocity of depolarization can
affect various myocardial regions in structurally
normal or abnormal hearts in different ways. This
might lead to changes in the absolute and relative
amplitudes of R- and S-waves, in QRS notches, and
in high frequency components of the ECG. There
is a great deal of literature on drug-induced incre-
ases in late potentials, reflecting the amplitude/
/morphology of these high frequency late transients
in the SAECG [3–7], but these changes do not per-
tain to the ECG. Changes in the QRS axis [13] may
result in changes in the morphology of some of the
ECG QRS complexes. A rightward shift of the ter-
minal 40 ms frontal plane QRS vector has been de-
scribed with tricyclic antidepressants [16], and this
would entail changes in QRS complex morphology.
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